Infectious diseases biobanking as a catalyst towards personalized medicine: Mycobacterium tuberculosis paradigm

Tuberculosis

Volumn 91, Issue 6, 2011, Pages 524-532

  Betsou, Fotini ^a   Parida, Shreemanta K ^b   Guillerm, Martine ^c  

^a INTEGRATED BIOBANK OF LUXEMBOURG   (Luxembourg)

^b Vaccine Grand Challenges Program   (India)

^c WHO Special Programme for Research and Training in Tropical Diseases (WHO/TDR)   (Switzerland)

Author keywords

Biobank; Biomarker; Infectious diseases; Tuberculosis

Indexed keywords

BIOLOGICAL MARKER; MOXIFLOXACIN; TUBERCULOSTATIC AGENT;

BLOOD SAMPLING; HUMAN; LUNG BIOPSY; LUNG LAVAGE; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PATIENT COMPLIANCE; PERICARDIAL EFFUSION; PRIORITY JOURNAL; PUBLIC HEALTH; REVIEW; SPUTUM; SPUTUM CULTURE; TUBERCULOSIS; URINALYSIS;

BIOLOGICAL MARKERS; BIOLOGICAL SPECIMEN BANKS; HUMANS; INDIVIDUALIZED MEDICINE; MYCOBACTERIUM TUBERCULOSIS; RESEARCH; TUBERCULOSIS;

EID: 80755136668     PISSN: 14729792     EISSN: 1873281X     Source Type: Journal    
DOI: 10.1016/j.tube.2011.07.006     Document Type: Review

References (41)

1. WHO World health statistics 2010 http://www.who.int/whosis/whostat/2010/ en/index.html
2. X. Li, Y. Yang, F. Zhou, Y. Zhang, H. Lu, Q. Jin, and L. Gao SLC11A1 (NRAMP1) polymorphisms and tuberculosis susceptibility: updated systematic review and meta-analysis PLoS One 6 1 2011 e15831
3. P.D. Van Helden, M. Möller, C. Babb, R. Warren, G. Walzl, P. Uys, and E. Hoal TB epidemiology and human genetics Novartis Found Symp 279 2006 17 31
4. Morbid Mortal Weekly Report 55 2006 1176
5. G. Walzl, K. Ronacher, J.F. Djoba Siawaya, and H.M. Dockrell Biomarkers for TB treatment response: challenges and future strategies J Infect 57 2008 103 109
6. C. Saltini, and V. Colizzi Soluble immunological markers of disease activity in tuberculosis Eur Respir J 14 1999 485 486 (Pubitemid 29479707)
7. R.S. Wallis, M. Pai, D. Menzies, T.M. Doherty, G. Walzl, M.D. Perkins, and A. Zumla Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practice Lancet 375 2010 1920 1937
8. H.E. Solberg Approved recommendations (1987) on the theory of reference values. Part 5. Statistical treatment of collected reference values: determination of reference limits Eur J Clin Chem Clin Biochem 25 1987 645 656
9. P.H.J. Riegman, M.M. Morente, F. Betsou, P. deBlasio, and P. Geary Marble Arch international working group on biobanking for biomedical research. Biobanking for better healthcare Mol Oncol 2 2008 213 222
10. F.M. Perrin, M.C. Lipman, T.D. McHugh, and S.H. Gillespie Biomarkers of treatment response in clinical trials of novel antituberculosis agents Lancet Infect Dis 7 2007 481 490 (Pubitemid 46962336)
11. http://www.genomeweb.com/print/947016.
12. M. Moller, F. Flachsbart, A. Till, T. Thye, R.D. Horstmann, C.G. Meyer, I. Osei, P.D. van Helden, E.G. Hoal, S. Schreiber, A. Nebel, and A. Franke A functional haplotype in the 3' untranslated region of TNFRSF1B is associated with tuberculosis in two African populations Am J Respir Crit Care Med 181 2010 388 393
13. X. Wang, Z. Cao, J. Jiang, H. Niu, M. Dong, A. Tong, and X. Cheng Association of mycobacterial antigen-specific CD4(+) memory T cell subsets with outcome of pulmonary tuberculosis J Infect 60 2010 133 139
14. S.D. Schuck, H. Mueller, F. Kunitz, A. Neher, H. Hoffmann, K.L. Franken, D. Repsilber, T.H. Ottenhoff, S.H. Kaufmann, and M. Jacobsen Identification of T-cell antigens specific for latent mycobacterium tuberculosis infection PLoS One 4 5 2009 e5590
15. J.F. Djoba Siwaya, N.N. Chegou, M.M. van den Heuvel, A.H. Diacon, N. Beyers, P. van Helden, and G. Walzl Differential cytokine/chemokines and KL-6 profiles in patients with different forms of tuberculosis Cytokine 47 2009 132 136
16. M. Ruhwald, T. Bodmer, C. Maier, M. Jepsen, M.B. Haaland, J. Eugen-Olsen, and P. Ravn Evaluating the potential of IP-10 and MCP-2 as biomarkers for the diagnosis of tuberculosis Eur Respir J 32 2008 1607 1615
17. D. Agranoff, D. Fernandez-Reyes, M.C. Papadopoulos, S.A. Rojas, M. Herbster, A. Loosemore, E. Tarelli, J. Sheldon, A. Schwenk, R. Pollok, C.F. Rayner, and S. Krishna Identification of diagnostic markers for tuberculosis by proteomic fingerprinting of serum Lancet 368 2006 1012 1021 (Pubitemid 44353670)
18. J.F. Djoba Siawaya, N.B. Bapela, K. Ronacher, H. Veenstra, M. Kidd, R. Gie, N. Beyers, P. van Helden, and G. Walzl Immune parameters as markers of tuberculosis extent of disease and early prediction of anti-tuberculosis chemotherapy response J Infect 56 2008 340 347
19. J.F. Djoba Siawaya, N.B. Bapela, K. Ronacher, N. Beyers, P. van Helden, and G. Walzl Differential expression of interleukin-4 (IL-4) and IL-4δ2 mRNA, but not transforming growth factor beta (TGF-βRII), Foxp3, gamma interferon, T-test, or GATA-3 mRNA, in patients with fast and slow responses to antituberculosis treatment Clin Vacc Immunol 15 2008 1165 1170
20. M. Jacobsen, D. Repsilber, A. Gutschmidt, A. Neher, K. Feldmann, H.J. Mollenkopf, A. Ziegler, and S.H. Kaufmann Candidate biomarkers for discrimination between infection and disease caused by Mycobacterium tuberculosis J Mol Med 85 2007 613 621 (Pubitemid 46876510)
21. R. Mistry, J.M. Cliff, C.L. Clayton, N. Beyers, Y.S. Mohamed, P.A. Wilson, H.M. Dockrell, D.M. Wallace, P.D. van Helden, K. Duncan, and P.T. Lukey Gene expression patterns in whole blood identify subjects at risk for recurrent tuberculosis J Infect Dis 195 2007 357 365 (Pubitemid 46146113)
22. J. Maertzdorf, D. Repsilber, S.K. Parida, K. Stanley, T. Roberts, G. Black, G. Walzl, and S.H. Kaufmann Human gene expression profiles of susceptibility and resistance in tuberculosis Genes Immun 12 2011 15 22
23. M.P. Berry, C.M. Graham, F.W. McNab, Z. Xu, S.A. Bloch, T. Oni, K.A. Wilkinson, R. Banchereau, J. Skinner, R.J. Wilkinson, C. Quinn, D. Blankenship, R. Dhawan, J.J. Cush, A. Mejias, O. Ramilo, O.M. Kon, V. Pascual, J. Banchereau, D. Chaussabel, and A. O'Garra An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis Nature 466 2010 973 977
24. C. Mehaffy, A. Hess, J.E. Prenni, B. Mathema, B. Kreiswirth, and K.M. Dobos Descriptive proteomic analysis shows protein variability between closely related clinical isolates of Mycobacterium tuberculosis Proteomics 10 2010 1966 1984
25. M. Coscolla, and S. Gagneux Does M. tuberculosis genomic diversity explain disease diversity? Drug Discov Today Dis Mech 7 2010 e43 e59
26. E.P. Diamandis Cancer biomarkers: can we turn recent failures into successes? J Natl Cancer Inst 102 2010 1462 1467
27. R. Ribeiro-Rodrigues, T. Resende Co, J.L. Johnson, F. Ribeiro, M. Palaci, R.T. Sá, E.L. Maciel, F.E. Pereira Lima, V. Dettoni, Z. Toossi, W.H. Boom, R. Dietze, J.J. Ellner, and C.S. Hirsch Sputum cytokine levels in patients with pulmonary tuberculosis as early markers of mycobacterial clearance Clin Diagn Lab Immunol 9 2002 818 823 (Pubitemid 34773884)
28. C.H. Chan, C.K. Lai, J.C. Leung, A.S. Ho, and K.N. Lai Elevated interleukin-2 receptor in patients with active pulmonary tuberculosis and the changes following anti-tuberculosis chemotherapy Eur Respir J 8 1995 70 73
29. Management of Tuberculosis; Training for health facility staff, WHO, 2nd ed. http://whqlibdoc.who.int/publications/2010/9789241598736b-eng.pdf.
30. J.M. Miller A guide to specimen management in clinical microbiology 2nd ed. 1999 ASM press
31. B.A. Forbes, N. Banaiee, K.G. Beavis, B.A. Brown-Elliott, P. Della Latta, and L.B. Elliott Laboratory detection and identification of Mycobacteria, approved guideline CLSI 2008 M48-A
32. F. Betsou, S. Lehmann, G. Ashton, M. Barnes, E.E. Benson, D. Coppola, Y. DeSouza, J. Eliason, B. Glazer, F. Guadagni, K. Harding, D.J. Horsfall, C. Kleeberger, U. Nanni, A. Prasad, K. Shea, A. Skubitz, S. Somiari, and E. Gunter International Society for biological and Environmental Repositories (ISBER) working group on biospecimen Science, standard preanalytical coding for biospecimens. Defining the sample PREanalytical Code (SPREC) Cancer Epidemiol Biomarkers Prev 19 2010 1004 1011
33. J. Lengellé, E. Panopoulos, and F. Betsou Soluble CD40-Ligand as a biomarker for storage-related preanalytic variations of human serum Cytokine 44 2008 275 282
34. K. Beaumont, and F. Betsou An immunological fingerprinting method for differentiation of serum samples in research-oriented biobanks Clin Vaccine Immunol 17 2010 735 740
35. F. Betsou, R. Barnes, T. Burke, D. Coppola, Y. Desouza, J. Eliason, B. Glazer, D. Horsfall, C. Kleeberger, S. Lehmann, A. Prasad, A. Skubitz, S. Somiari, and E. Gunter International Society for biological and Environmental Repositories (ISBER) working group on biospecimen Science. Human biospecimen research: experimental protocol and quality control tools Cancer Epidemiol Biomarkers Prev 18 2009 1017 1025
36. K. Pitt, L.D. Campbell, A.P.N. Skubitz, S.B. Somiari, K.C. Sexton, R.S. Pugh, R. Aamodt, and P. Baird Best practices for repositories: collection storage, retrieval and distribution of biological materials for research Cell Preservation Technol 6 2008 5 58
37. D.O. Fleming, and D.L. Hunt Biological safety, principles and practices 4th ed. 2006 ASM Press
38. J.J. Yim, and P. Selvaraj Genetic susceptibility in tuberculosis Respirology 15 2010 241 256
39. T. Souza, R. Kush, and J.P. Evans Global clinical data interchange standards are here! Drug Discover Today 12 2007 174 181 (Pubitemid 46188409)
40. S. Ekins, J.S. Freundlich, I. Choi, M. Sarker, and C. Talcott Computational databases, pathway and cheminformatics tools for tuberculosis drug discovery Trends Microbiol 19 2011 65 74
41. A. Carter, and F. Betsou Quality assurance in cancer biobanking Biopreserv Biobanking 9 2011 157 163